Kiora Pharmaceuticals, Inc.
KPRX
$2.50
-$0.08-3.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -24,415.30% | 101.25% | 1.85% | 48.08% | -23.74% |
| Total Depreciation and Amortization | 218.59% | 21.27% | 60.71% | 12.64% | 22.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 420.55% | -465.34% | -2.45% | 367.31% | -114.66% |
| Change in Net Operating Assets | -507.13% | 104.20% | -122.69% | -144.25% | -36.23% |
| Cash from Operations | -71.27% | 66.53% | -40.65% | -20.06% | -344.80% |
| Capital Expenditure | -19,450.00% | 98.76% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.46% | 724.38% | -73.94% | 510.65% | 122.79% |
| Cash from Investing | -6.82% | 764.29% | -75.15% | 453.72% | 125.14% |
| Total Debt Issued | -100.00% | 75.00% | -- | -- | -- |
| Total Debt Repaid | 100.00% | -75.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 42.42% | -89.97% | 1,202.97% | 113.38% | -221.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.86% | 263.39% | -12,774.65% | 98.85% | -96.72% |